Ph D Thesis Gopinadh Bhyrapuneni 0603PH0489 -...
Transcript of Ph D Thesis Gopinadh Bhyrapuneni 0603PH0489 -...
136
References
137
REFERENCES
1. Chicharro JL, Lucia A, Perez M, Vaquero AF, Urena R. “Saliva
composition and exercise”. Sports Med. 26, 1998, 17.
2. Manohara Reddy SA, Mudgal J, Bansal P, Vasanthraju SG,
Srinivasan KK, Rao CM, Gopalan Kutty N. “Antioxidant, anti-
inflammatory and anti-hyperglycaemic activities of heterocyclic
homoprostanoid derivatives”. Bioorg. Med. Chem. 19, 2011,384.
3. Frankmann SP. “A technique for repeated sampling of CSF from
the anesthetized rat”. Physiol. Behav. 37, 1986, 489.
4. Huestis MA, Cone EJ. Alternative testing matrices. In: Karch
SB, ed. Drug Abuse Handbook. Boca Raton, FL: CRC Press,
1998, 799–857.
5. Andes D, Stamsted T, Conklin R. “Pharmacodynamics of
amphotericin B in a neutropenic-mouse disseminated-
candidiasis model”. Antimicrob. Agents Chemother. 45, 2001,
922.
6. Caricato A, Pennisi M, Mancino A, Vigna G, Sandroni C,
Arcangeli C, Antonelli M. “Levels of vancomycin in the cerebral
interstitial fluid after severe head injury”. Intensive Care Med.
32, 2006, 325.
7. Nirogi R, Kandikere V, Mudigonda K, Bhyrapuneni G, Muddana
N, Saralaya R, Benade V. "A simple and rapid method to collect
the cerebrospinal fluid of rats and its application for the
138
assessment of drug penetration into the central nervous
system". J. Neurosci. Methods. 178, 2009, 116.
8. Chandra S. Chaurasia, Markus Müller, Edward D. Bashaw, Eva
Benfeldt,Jan Bolinder, Ross Bullock, Peter M. Bungay, Elizabeth
C.M. DeLange, Hartmut Derendorf, William F. Elmquist,
Margareta Hammarlund-Udenaes, Christian Joukhadar, Dean
L. Kellogg, Jr, Craig E. Lunte, Carl Henrik Nordstrom, Hans
Rollema, Ronald J. Sawchuk, Belinda W.Y. Cheung, Vinod P.
Shah, Lars Stahle, Urban Ungerstedt, Devin F. Welty, Helen
Yeo. “AAPS-FDA Workshop White Paper: Microdialysis
Principles, Application, and Regulatory Perspectives”. Report
From the Joint AAPS-FDA Workshop, November 4-5, 2005,
Nashville, TN. The AAPS Journal. 9, 2007, E48.
9. Chernet E, Martin LJ, Li D, Need AB, Barth VN, Rash KS,
Phebus LA. “Use of LC/MS to assess brain tracer distribution in
preclinical, in vivo receptor occupancy studies: Dopamine D2,
serotonin 2A and NK-1 receptors as examples”. Life Sci. 78,
2005, 340.
10. Idkaidek N, Arafat T. "Saliva versus Plasma Pharmacokinetics:
Theory and Application of a Salivary Excretion Classification
System". Mol. Pharm. 9, 2012, 2358.
11. Ruiz ME, Conforti P, Fagiolino P, Volonté MG. "The use of saliva
as a biological fluid in relative bioavailability studies:
139
comparison and correlation with plasma results". Biopharm.
Drug Dispos. 31, 2010, 476.
12. Smith JN, Wang J, Lin Y, Klohe EM, Timchalk C.
"Pharmacokinetics and Pharmacodynamics of Chlorpyrifos and
3,5,6-Trichloro-2-pyridinol (TCPy) in Rat Saliva After
Chlorpyrifos Administration". Toxicol. Sci. 2012.Aug 8 [Epub
ahead of print]
13. Fabritius M, Staub C, Mangin P, Giroud C. "Distribution of free
and conjugated cannabinoids in human bile samples". Forensic
Sci. Int. 2012, doi: 10.1016/j.forsciint.2012.08.013 [Epub
ahead of print]
14. Zhou L, Dockens RC, Liu-Kreyche P, Grossman SJ, Iyer RA. "In
vitro and in vivo metabolism and pharmacokinetics of BMS-
562086, a potent and orally bioavailable corticotropin-releasing
factor-1 receptor antagonist". Drug Metab. Dispos. 40, 2012,
1093.
15. Barnes AJ, Brunet BR, Choo RE, Mura P, Johnson RE, Jones
HE, Huestis MA."Excretion of methadone in sweat of pregnant
women throughout gestation after controlled methadone
administration". Ther. Drug Monit. 32, 2010, 497.
16. Dear GJ, Beaumont C, Roberts A, Squillaci B, Thomas S, Nash
M, Fraser D. “Approaches for the rapid identification of drug
metabolites in early clinical studies”. Bioanalysis. 3, 2011, 197.
140
17. Dhaneshwar SS, Gairola N, Kandpal M, Vadnerkar G, Bhatt L,
Rathi B, Kadam SS. “Synthesis, kinetic studies and
pharmacological evaluation of mutual azo prodrugs of 5-
aminosalicylic acid for colon-specific drug delivery in
inflammatory bowel disease”. Eur. J. Med. Chem. 44, 2009,
3922.
18. Bhatta RS, Chandasana H, Rathi C, Kumar D, Chhonker YS,
Jain GK. “Bioanalytical method development and validation of
natamycin in rabbit tears and its application to ocular
pharmacokinetic studies”. J. Pharm. Biomed. Anal. 54, 2011,
1096.
19. Prasanthi S, Vidyavathi M, Prasad KV, Krishna DR. “O-
demethylation of dextromethorphan using microbial
cultures”.Drug. Metab. Lett. 3, 2009, 10.
20. Matsu DM. "Therapeutic drug monitoring in pregnancy". Ther.
Drug Moni. 34, 2012, 207.
21. Nechuta S, Mudd LM, Elliott MR, Lepkowski JM, Paneth N;
“Michigan Alliance for the National Children's Study. Attitudes
of pregnant women towards collection of biological specimens
during pregnancy and at birth”. Paediatr. Perinat. Epidemiol. 26,
2012, 272.
22. Concheiro M, Jones HE, Johnson RE, Choo R, Huestis MA.
"Preliminary buprenorphine sublingual tablet pharmacokinetic
141
data in plasma, oral fluid, and sweat during treatment of opioid-
dependent pregnant women". Ther. Drug Monit. 33, 2011,619.
23. Kidwell DA, Holland JC, Athanaselis S. “Testing for drugs of
abuse in saliva and sweat”. J. Chromatogr. B. Biomed. Sci. Appl.
713, 1998, 111.
24. Atkinson HC, Begg EJ, Darlow BA. "Drugs in human milk.
Clinical pharmacokinetic considerations". Clin.
Pharmacokinet.14, 1988, 217.
25. Fortinguerra F, Clavenna A, Bonati M. "Psychotropic drug use
during breastfeeding: a review of the evidence". Pediatrics. 124,
2009, 547.
26. Halstead AC, Godolphin W, Lockitch G, et al. “Timing of
specimen collection is crucial in urine screening of drug
dependent mothers and newborns”. Clin. Biochem. 21, 1988,
59.
27. Graham K, Koren G, Klein J, et al. “Determination of gestational
cocaine exposure by hair analysis”. JAMA.262, 1989, 3328.
28. Vähäkangas K, Myllynen P. "Drug transporters in the human
blood-placental barrier". Br. J. Pharmacol. 158, 2009, 665.
29. Brown SD, Bartlett MG, White CA. "Pharmacokinetics of
intravenous acyclovir, zidovudine, and acyclovir-zidovudine in
pregnant rats". Antimicrob. Agents Chemother.47, 2003, 991.
142
30. Nirogi R, Bhyrapuneni G, Kandikere V, Muddana N, Saralaya R,
Komarneni P, Mudigonda K, Mukkanti K."Pharmacokinetic
profiling of efavirenz-emtricitabine-tenofovir fixed dose
combination in pregnant and non-pregnant rats". Biopharm.
Drug Dispos. 33, 2012, 265.
31. Montgomery D, Plate C, Alder SC, Jones M, Jones J,
Christensen RD. "Testing for fetal exposure to illicit drugs using
umbilical cord tissue vs meconium". J. Perinatol. 26, 2006, 11.
32. Stolk LM. "Meconium as a matrix". Clin. Pharmacokinet. 31,
1996, 81.
33. Gareri J, Klein J, Koren G."Drugs of abuse testing in
meconium". Clin. Chim. Acta. 366, 2006, 101.
34. Nageswara Rao R, Guruprasad K, Gangu Naidu Ch, Raju B,
Srinivas R.”LC-ESI-MS/MS determination of in vivo metabolites
of almotriptan in rat plasma, urine and feces: application to
pharmacokinetics”. J Chromatogr B Analyt Technol Biomed Life
Sci.891-892,2012,44.
35. Marchei E, Papaseit E, Garcia-Algar OQ, Farrè M, Pacifici R,
Pichini S. "Determination of atomoxetine and its metabolites in
conventional and non-conventional biological matrices by
liquid chromatography-tandem mass spectrometry". J Pharm
Biomed Anal. 60, 2012, 26.
143
36. Kielbasa W, Kalvass JC, Stratford R."Microdialysis evaluation of
atomoxetine brain penetration and central nervous system
pharmacokinetics in rats". Drug Metab Dispos. 37,2009, 137.
37. Mattiuz EL, Ponsler GD, Barbuch RJ, Wood PG, Mullen JH,
Shugert RL, Li Q, Wheeler WJ, Kuo F, Conrad PC, Sauer JM.
"Disposition and metabolic fate of atomoxetine hydrochloride:
pharmacokinetics, metabolism, and excretion in the Fischer 344
rat and beagle dog". Drug Metab Dispos. 2003 Jan;31(1):88-97.
38. Korth-Bradley JM, Parks V, Chalon S, Gourley I, Matschke K,
Gossart S, Bryson P, Fleckenstein L. "Excretion of moxidectin
into breast milk and pharmacokinetics in healthy lactating
women". Antimicrob Agents Chemother. 55, 2011, 5200.
39. Tabernero MJ, Felli ML, Bermejo AM, Chiarotti M.
"Determination of ketamine and amphetamines in hair by
LC/MS/MS". Anal Bioanal Chem. 395, 2009, 2547.
40. Gray TR, Shakleya DM, Huestis MA."A liquid chromatography
tandem mass spectrometry method for the simultaneous
quantification of 20 drugs of abuse and metabolites in human
meconium". Anal Bioanal Chem. 393, 2009, 1977.
41. Simon V, Ho DD. “HIV/AIDS epidemiology, pathogenesis,
prevention, and treatment”. Lancet. 368 (9534), 2006, 489.
42. Molina JM. “Efficacy and safety of once-daily regimens in the
treatment of HIV infection”. Drugs 68, 2008, 567.
144
43. Satyanarayana K, Srivastava S. “Universal access to HIV/AIDS
treatment: challenges ahead”. Indian J. Med. Res. 130 (6), 2009,
671.
44. http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescent
45. Palella FJJ, Delane KM, Moorman AC, Aschman DJ, Holmberg
SD (1998). “Declining morbidity and mortality among patients
with advanced human immunodeficiency virus infection”. N.
Engl. J. Med. 338, 1998, 853.
46. http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/0
21752s030lbl.pdf
47. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/
index.cfm? fuseaction=Search.DrugDetails
48. David W, Jason B, Zelalem T. “Antiretroviral Drugs”. J. Clin.
Pharmacol. 47, 2007, 1570.
49. Prabhakar K, Afzal SM, Kumar PU, Rajanna A, Kishan V. “Brain
delivery of transferrin coupled indinavir submicron lipid
emulsions--pharmacokinetics and tissue distribution”. Colloids
Surf. B Biointerfaces. 86, 2011, 305.
50. Kola I, Landis J. “Opinion: can the pharmaceutical industry
reduce attrition rates?”. Nat. Rev. Drug Discov. 3, 2004, 711.
51. Alavijeh MS, Chishty M, Qaiser MZ, Palmer AM. “Drug
metabolism and pharmacokinetics, the blood-brain barrier, and
central nervous system drug discovery”. NeuroRx. 2, 2005, 554.
145
52. Pardridge WM. “Blood-brain barrier delivery”. Drug Discov.
Today 12, 2007, 54.
53. Fagerholm U. “The highly permeable blood-brain barrier: an
evaluation of current opinions about brain uptake capacity”.
Drug Discov Today. 12, 2007, 1076.
54. Kumar YS, Adukondalu D, Sathish D, Vishnu YV, Ramesh G,
Latha AB, Reddy PC, Sarangapani M, Rao YM. “P-Glycoprotein-
and cytochrome P-450-mediated herbal drug interactions”. Drug
Metabol. Drug Interact. 25, 2010:3.
55. Venishetty VK, Samala R, Komuravelli R, Kuncha M, Sistla R,
Diwan PV. β-Hydroxybutyric acid grafted solid lipid
nanoparticles: A novel strategy to improve drug delivery to
brain. Nanomedicine. 2012. doi: 10.1016/j.nano.2012.08.004.
56. Tovo PA, Newell ML, Mandelbrot L, Semprini A, Giaquinto C.
“Recommendations for the management of HIV infected women
and their infants”. A European Consensus. Luxembourg:
European Commission, 1999, 1.
57. Kind C, Rudin C, Siegrist CA.”Prevention of vertical HIV
transmission: additive protective effect of elective Cesarean
section and zidovudine prophylaxis”. AIDS. 12, 1998, 205.
58. Blattner W, Cooper E, Charurat M. “Effectiveness of potent
antiretroviral therapies on reducing perinatal transmission of
146
HIV-1”. XIII International Conference on AIDS. Durban. 2000,
[abstract LbOr4].
59. Lorenzi P, Spicher VM, Laubereau B. “Antiretroviral therapies
in pregnancy: maternal, fetal and neonatal effects”. AIDS. 12,
1998, F241.
60. Thorne C. “For the European Collaborative Study.
“Antiretroviral therapy and caesarean section to reduce vertical
transmission of HIV in Europe”. XIII International Conference
on AIDS, Durban, 2000, abstract (MoOrC240).
61. Mocroft A, Ruiz L, Reiss P, Ledergerber B, Katlama C, Lazzarin
A, Goebel FD, Phillips AN, Clotet B, Lundgren JD. “Virological
rebound after suppression on highly active antiretroviral
therapy”. AIDS 17, 2003, 1741.
62. Ledergerber B, Egger M, Opravil M, Telenti A, Hirschel B,
Battegay M, Vernazza P, Sudre P, Flepp M, Furrer H, Francioli
P, Weber R. “Clinical progression and virological failure on
highly active antiretroviral therapy in HIV-1 patients: a
prospective cohort study. Swiss HIV Cohort Study”. Lancet. 353,
1999, 863.
63. Gedeon C, Koren G. “Designing Pregnancy Centered
Medications: Drugs Which Do Not Cross the Human Placenta”.
Placenta. 27, 2005; 1.
147
64. Nirogi R, Bhyrapuneni G, Kandikere V, Mudigonda K,
Komarneni P, Aleti R, Mukkanti K. “Simultaneous
quantification of a non-nucleoside reverse transcriptase
inhibitor efavirenz, a nucleoside reverse transcriptase inhibitor
emtricitabine and a nucleotide reverse transcriptase inhibitor
tenofovir in plasma by liquid chromatography positive ion
electrospray tandem mass spectrometry”. Biomed. Chromatogr.
23, 2009, 371.
65. Blum MR, Chittick GE, Begley JA, Zong J. “Steady-state
pharmacokinetics of emtricitabine and tenofovir disoproxil
fumarate administered alone and in combination in healthy
volunteers”. J. Clin. Pharmacol. 47, 2007, 751.
66. Ramanathan G, Shen G, Cheng A, Kearney BP.
“Pharmacokinetics of emtricitabine, tenofovir, and GS-9137
following coadministration of emtricitabine/tenofovir disoproxil
fumarate and ritonavir-boosted GS-9137”. J. Acquir. Immune.
Defic. Syndr. 45, 2007, 274.
67. Cao J, Huang L, Liu Y, Hoffman T, Stieger B, Meier PJ, Vore M.
“Differential regulation of hepatic bile salt and organic anion
transporters in pregnant and postpartum rats and the role of
prolactin”. Hepatology. 33, 2001, 140.
68. Jedlitschky G, Leier I, Buchholz U, Center M, and Keppler D.
“ATP-dependent transport of glutathione S-conjugates by the
148
multidrug resistance-associated protein”. Cancer Res. 54. 1994,
4833.
69. Jedlitschky G, Leier I, Buchholz U, Barnouin K, Kurz G, and
Keppler D. “Transport of glutathione, glucuronate, and sulfate
conjugates by the MRP gene-encoded conjugate export pump”.
Cancer Res. 56, 1996, 988.
70. Keppler D, Konig J. “Hepatic canalicular membrane 5:
expression and localization of the conjugate export pump
encoded by the MRP2 (cMRP/cMOAT) gene in liver”. FASEB. J.
11, 1997, 509.
71. Suzuki H, Sugiyama Y. “Excretion of GSSG and glutathione
conjugates mediated by MRP1 and cMOAT/MRP2". Semin. Liver
Dis. 18, 1998, 359.
72. Weiss J, Theile D, Ketabi-Kiyanvash N, Lindenmaier H, Haefeli
WE. “Inhibition of MRP1/ABCC1, MRP2/ABCC2, and
MRP3/ABCC3 by Nucleoside, Nucleotide and Non-Nucleoside
Reverse Transcriptase Inhibitors”. Drug Metab. Dispos. 35,
2007, 340.
73. Foster C, Lyall H, Olmscheid B, Pearce G, Zhang S, Gibb DM.
“Tenofovir disoproxil fumarate in pregnancy and prevention of
mother-to-child transmission of HIV-1: Is it time to move on
from zidovudine”. HIV Med. 10(7), 2009,397.
149
74. Tarantal AF, Castillo A, Ekert JE, Bischofberger N, Martin RB.
“Fetal and maternal outcome after administration of Tenofovir to
gravid Rhesus Monkeys (Macaca mulatta)”. J. Acquir. Immune.
Defic Syndr. 29, 2002, 207.
75. Hutson JR, Koren G, Matthews SG. “Placental P-glycoprotein
and breast cancer resistance protein: Influence of
polymorphisms on fetal drug exposure and physiology”.
Placenta. 31, 2010, 351.
76. Macfarland A, Abramovich DR, Ewen SW, Pearson CK. “Stage-
specific distribution of P-glycoprotein in first-trimester and full-
term human placenta”. Histochem. J. 26, 1994, 417.
77. Meyer ZU Schwabedissen HE, Jedlitschky G, Gratz M, Haenisch
S, Linnemann K, Fusch C, Cascorbi I, Kroemer HK. “Variable
expression of MRP2 (ABCC2) in human placenta: Influence of
gestational age and cellular differentiation”. Drug Metab. Dispos.
33, 2005, 896.
78. St-Pierre MV, Serrano MA, Macias RI, Dubs U, Hoechli M,
Lauper U, Meier PJ, Marin JJ. “Expression of members of
multidrug resistance protein family in human term placenta”.
Am. J. Physiol. Regul. Integr. Comp. Physiol. 279, 2007, R1495.
79. Imaoka T, Kusuhara H, Adachi M, Schuetz JD, Takeuchi K,
Sugiyama Y. “Functional involvement of multidrug resistance-
associated protein 4 (MRP4/ABCC4) in the renal elimination of
150
the antiviral drugs adefovir and tenofovir”. Mol. Pharmacol. 71,
2007, 619.
80. Ray AS, Cihlar T, Robinson KL, Tong L, Vela JE, Fuller MD,
Wieman LM, Eisenberg EJ, Rhodes GR. “Mechanism of active
renal tubular efflux of tenofovir”. Antimicrob. Agents Chemother.
50, 2006, 3297.
81. Cheer SM and Wagstuff AJ. “Quetiapine: a review of its use in
the management of schizophrenia”. CNS Drugs. 18, 2004, 173.
82. Seroquel;http://www.astrazeneca.com/productbrowse/4_77.as
p, dated January 10, 2008.
83. Bezchlibnyk-Butler KZ and Jeffries JJ. “Clinical Handbook of
Psychotropic Drugs”. Hogrefe & Huber Publishers, Toronto,
1999.
84. Kapur S, Wadenberg ML, and Remington G. “Are animal studies
of antipsychotics appropriately dosed? Lessons from the bedside
to the bench”. Can. J. Psychiatry. 45, 2000, 241.
85. Ereshefsky L. “Pharmacokinetics and drug interactions:
updated for new antipsychotics”. Journal of clinical Psychiatry.
57, 1996, 12.
86. Goren JL and Levin GM. “Quetiapine and atypical
antipsychotic”. Pharmacotherapy. 18, 1998, 1183.
151
87. Markowitz JS, Brown CS, Moore TR. “Part 1: Pharmacology,
pharmacokinetics and efficacy”. The Annals of Pharmacotherphy
.33, 1999, 73.
88. Paxinos G and Watson C. “Rat brain in stereotaxic coordinates”.
Academic Press, New York, 2004.
89. Nirogi R, Bhyrapuneni G, Kandikere V, Mudigonda K, Ajjala D,
Mukkanti K. “Sensitive liquid chromatography tandem mass
spectrometry method for the quantification of Quetiapine in
plasma”. Biomedical Chromatography. 22, 2008, 1043.
90. Davis PC, Wong J and Gefvert O. “Analysis and
pharmacokinetics of quetiapine and two metabolites in human
plasma using reversed phase HPLC with ultraviolet and
electrochemical detection”. Journal of Pharmaceutical and
Biomedical Analysis. 20, 1999, 271.
91. Hasselstrom J and Linnet K. “Fully automated online
quantification of quetiapine in human serum by solid phase
extraction and liquid chromatography”. Journal of
Chromatography B. 798, 2003, 9.
92. Mandrioli R, Fanali S, Ferranti A and Raggi MA. “HPLC analysis
of the novel antipsychotic drug quetiapine in human plasma”.
Journal of Pharmaceutical and Biomedical Analysis. 30, 2002,
969.
152
93. Mercolini L, Grillo M, Bartoletti C, Boncompagni G and Raggi
MA. “Simultaneous analysis of classical neuroleptics, atypical
antipsychotics and their metabolites in human plasma”.
Analytical Bioanalytical Chemistry. 388, 2007, 235.
94. Sachse J, Koller J, Hartter S and Hiemke C. “Automated
analysis of quetiapine and other antipsychotic drugs in human
blood by high performance liquid chromatography with column-
switching and spectrophotometric detection”. Journal of
Chromatography B. 830, 2006, 342.
95. Saracino MA, Mercolini L, Flotta G, Albers LJ, Merli R and Raggi
MA. “Simultaneous determination of fluvoxamine isomers and
quetiapine in human plasma by means of high-performance
liquid chromatography”. Journal of Chromatography B. 843,
2006, 227.
96. Fisher DS, Handley SA, Taylor D, Flanagan RJ. "Measurement
of quetiapine and four quetiapine metabolites in human plasma
by LC-MS/MS". Biomed. Chromatogr. 26, 2012, 1125.
97. Davis PC, Bravo O, Gehrke M, Azumaya CT. "Development and
validation of an LC-MS/MS method for the determination of
quetiapine and four related metabolites in human plasma". J.
Pharm. Biomed. Anal. 51, 2010, 1113.
98. Nuutinen JM, Ratilainen J, Rissanen K, Vainiotalo P. “Mass
spectrometric studies on small open-chain piperazine-
153
containing ligands and their transition metal complexes”.
Journal of Mass Spectrometry. 36, 2001, 902.
99. Matheson Anna J and Lamb Harriet M. “Quetiapine: A review of
its clinical potential in the management of psychotic symptoms
in parkinson’s disease”. CNS Drugs. 14, 2000, 157.
100. Edell WS, Tunis SL. “Antipsychotic treatment of behavioral and
psychological symptoms of dementia in geropsychiatric
inpatients”. Am. J. Geriatr. Psychiatry. 9, 2001, 289.
101. Madhusoodanan S, Brenner R, Cohen CI. “Role of atypical
antipsychotics in the treatment of psychosis and agitation
associated with dementia”. CNS Drugs. 12, 1999, 135.
102. Grutzendler J, Morris C. “Cholinesterase inhibitors for
Alzheimer’s disease”. Drugs. 61, 2001, 41.
103. Seltzer B. “Donepezil: an update”. Expert Opin. Pharmacother. 8,
2007, 1011.
104. Reynolds PL, Strayer SM. “Neuroleptics for behavioral symptoms
of dementia”. J. Fam. Pract. 49, 1999, 78.
105. De Deyn PP, Rabheru K, Rasmussen A, Bocksberger JP,
Dautzenberg PL, Eriksson S, Lawlor BA. “A randomized trial of
risperidone, placebo and haloperidol for behavioral symptoms in
dementia”. Neurology. 53, 1999, 946.
154
106. Hsing-Cheng L, Shih-Ku L, Sing-Ming S. “Extrapyramidal side
effects due to drug combination of risperidone and donepezil”.
Psychiatry Clin. Neurosci. 56, 2002, 479.
107. Parsa MA, Poggi E, Barte L. “Treatment of dementia patients
with psychotic and behavioral symptoms with quetiapine and
donepezil”. Eur. Neuropsychopharmacol. 10, 2002, 302.
108. US Food and Drug Administration (2005) FDA public health
advisory- deaths with antipsychotics in elderly patients with
behavioural disturbances. FDA/ center for drug evaluation and
research.www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafet
yInformationforPatientsandProviders/DrugSafetyInformationfor
HealthcareProfessionals/PublicHealthAdvisors/UCMOS3171.ht
m. Accessed 30 November 2011.
109. US Food and Drug Administration (2008) Information for
healthcare professionals: conventional antipsychotics.
FDA/center for drug evaluation and research.
www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformat
ionforPatientsandProviders/UCM124830.htm. Accessed 30
November 2011.
110. Bauman W, Pinner G. “Use of atypical antipsychotic drugs in
old age psychiatry”. Adv. Psychiatr. Treat. 8, 2002, 49.
111. Carcenac D, Martin-Hunyadi C, Kiesmann M, Demuynck-Roegel
C, Alt M, Kuntzmann F. “Extra-pyramidal syndrome induced by
donepezil”. Presse. Med. 29, 2000, 992.
155
112. Bentu´e-Ferrer D, Tribut O, Polard E, Allain H. “Clinically
significant drug interactions with cholinesterase inhibitors: a
guide for neurologists”. CNS Drugs. 17, 2003, 947.
113. Arai M. “Parkinsonism onset in a patient concurrently using
tiapride and donepezil”. Intern. Med. 39, 2000, 863.
114. Magnuson TM, Keller BK, Burke WJ. “Extrapyramidal side
effects in a patient treated with risperidone plus donepezil”. Am.
J. Psychiatry. 155, 1998, 1458.
115. Katner S, Bymaster F, Davis R, Nomikos G, Kennedy J, Perry K.
“The combination of olanzapine and donepezil increases
extracellular concentrations of dopamine and acetylcholine in
rat prefrontal cortex”. Proceedings of the 11th International
Conference on In Vivo Methods. 2006, 475.
116. Kosasa T, Kuriya Y, Matsui K, Yamanishi Y. “Effect of donepezil
hydrochloride (E2020) on basal concentration of extracellular
acetylcholine in the hippocampus of rats”. Eur. J. Pharmacol.
380, 1999, 101.
117. Nirogi R, Bhyrapuneni G, Kandikere V, Benade V, Muddana N,
Saralaya R, Irappanavar S, Ponnamaneni R, Mukkanti K.
“Concurrent administration of atypical antipsychotics and
donepezil: drug interaction study in rats”. Eur. J. Drug Metab.
Pharmacokinet. 37, 2012, 155.
156
118. Matsui K, Mishima M, Nagai Y, Yuzuriha T, Yoshimura T.
“Absorption, distribution, metabolism, and excretion of
donepezil (Aricept) after a single oral administration to Rat”.
Drug Metab. Dispos. 27, 1999, 1406.
119. Sharif ZA. “Pharmacokinetics, metabolism, and drug-drug
interactions of atypical antipsychotics in special populations.
Primary care companion”. J. Clin. Psychiatry. 5, 2003, 22.
120. Graylands Hospital Drug Bulletin 14 (1) 2006
http://www.Watag.org.au/wapdc/docs/GDB%2014-
2%20July06.pdf. Accessed 30 Nov 2011.
121. Barth VN, Chernet E, Martin LJ, Need AB, Rash KS, Morin M,
Phebus LA.. “Comparison of rat dopamine D2 receptor
occupancy for a series of antipsychotic drugs measured using
radio labeled or nonlabeled raclopride tracer”. Life Sci. 78,
2006, 3007.
122. Need AB, McKinzie JH, Mitch CH, Statnick MA, Phebus LA. “In
vivo rat brain opioid receptor binding of LY255582 assessed
with a novel method using LC/MS/MS and the administration
of three tracers simultaneously”. Life Sci. 81, 2007, 1389.
123. Nirogi R, Kandikere V, Bhyrapuneni G, Muddana N, Saralaya R,
Ponnamaneni RK, Manoharan AK. “In vivo receptor occupancy
assay of histamine H3 receptor antagonist in rats using non-
radiolabeled tracer”. Journal of Pharmacological and Toxicological
Methods. 65, 2012, 115.
157
124. Nirogi R, Kandikere V, Bhyrapuneni G, Saralaya R, Muddana N,
Ajjala DR. “Rat thalamic α4β2 neuronal nicotinic acetylcholine
receptor occupancy assay using LC-MS/MS”. Journal of
Pharmacological and Toxicological Methods. 65, 2012, 136.
125. Dajas BF, Wonnacott S (2004). “Nicotinic acetylcholine receptors
and the regulation of neuronal signalling”. Trends Pharmacol
Sci. 6, 2004, 317.
126. Sihver W, Nordberg A, Langstrom B, Mukhin AG, Koren AO,
Kimes AS, London ED. “Development of ligands for in vivo
imaging of cerebral nicotinic receptors”. Behav Brain Res. 113,
2000, 43.
127. Thomsen MS, Hansen HH, Timmerman DB, Mikkelsen JD.
“Cognitive improvement by activation of alpha7 nicotinic
acetylcholine receptors:from animal models to human
pathophysiology”. Curr. Pharm. Des. 16, 2010, 323.
128. MacAllan DRE, Lunt GG, Wonnacott S, Swanson KL, Rapoport
H, Albuquerque EX. “Methyllycaconitine and -anatoxin a
differentiate between nicotinic receptors in vertebrate and
invertebrate nervous systems”. FEBS Lett. 226, 1988, 357.
129. Nambi-Aiyar V, Benn MH, Hanna T, Jacyno J, Roth SH, Wilkins
JL. “The principle toxin of Delphinium brownie (Rydb.) and its
mode of action”. Experientia. 35, 1979, 1367.
158
130. Palma E, Bertrand S, Binzoni T, Bertrand D. “Neuronal 7
receptor expressed in Xenopus oocytes presents five putative
binding sites for methyllycaconitine”. J. Physiol. 491, 1996,
151.
131. Ward, J. M., Cockroft, V. B., Lunt, G. G., Smillie, F. S., &
Wonnacott, S. “Methyllycaconitine: A selective probe for
neuronal bungarotoxin binding site”. FEBS Letters 270, 1990,
45.
132. Wonnacott S, Albuquerque EX, Bertrand D. “Methyllycaconitine:
a new probe that discriminates between nicotinic acetylcholine
receptor subclasses”. Methods Neurosci. 12, 1993, 263.
133. Davies ARL, Hardick DJ, Blagbrough IS, Potter BVL,
Wolstenholme AJ, Wonnacott S. “Characterization of the binding
of [3H] methyllycaconitine: a new radioligand for labeling a7-
type neuronal nicotinic acetylcholine receptors”.
Neuropsychopharmacol. 38, 1999, 679.
134. Donna LM, Geraldine H, Min D, uke D, Einstein E, Gurley D,
Gordon JC, Bock MJ, Smith JS, Bialecki R, Eisman M, Elmore
CS, Werkheiser JL. “Pre-clinical validation of a novel alpha-7
nicotinic receptor radiotracer, [3H] AZ11637326: Target
localization, biodistribution and ligand occupancy in the rat
brain”. Neuropharmacol. 61, 2011, 161.